Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. to Present at the Deutsche Bank 40th Annual Health Care Conference
May 1, 2015
PDF 13.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on First Quarter 2015 Financial Results and Business Update
Apr 30, 2015
PDF 14.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Presents Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting
Apr 20, 2015
PDF 17.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results and Business Update
Mar 11, 2015
PDF 30.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2014 Financial Results and Business Update
Mar 10, 2015
PDF 108.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 27th Annual ROTH Conference
Mar 6, 2015
PDF 106.0 KB Add to Briefcase
View Summary TG Therapeutics Enters Into a Global Collaboration With Checkpoint Therapeutics to Develop and Commercialize Novel Immuno-Oncology Targeted Antibodies
Mar 4, 2015
PDF 112.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the Cowen and Company 35th Annual Health Care Conference
Mar 2, 2015
PDF 106.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 17th Annual BIO CEO & Investor Conference
Feb 4, 2015
PDF 106.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Provide an Update on Its Clinical Programs and Corporate Goals for 2015 at the 33rd Annual J.P. Morgan Healthcare Conference
Jan 15, 2015
PDF 109.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Jan 8, 2015
PDF 106.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
Dec 17, 2014
PDF 109.6 KB Add to Briefcase
View Summary Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety
Dec 9, 2014
PDF 118.0 KB Add to Briefcase
View Summary Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)
Dec 8, 2014
PDF 160.5 KB Add to Briefcase
View Summary Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Dec 6, 2014
PDF 196.6 KB Add to Briefcase
View Summary TG Therapeutics Announces Collaboration for a Clinical Trial of TGR-1202 in Combination With Ibrutinib (Imbruvica(R)) for Patients With Select B-Cell Malignancies
Dec 1, 2014
PDF 111.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 2014 Deutsche Bank BioFEST Conference
Nov 25, 2014
PDF 13.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
Nov 10, 2014
PDF 118.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
Nov 7, 2014
PDF 106.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
Nov 6, 2014
PDF 113.9 KB Add to Briefcase
Showing 81-100 of 174 Page: 1 2 3 4 5 6 7 8 9  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase